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Uterine smooth muscle tumours are the most common neoplasm in
the female genital tract. They are histologically classified into
several subtypes: usual leiomyoma (UL), cellular leiomyoma
(CL), bizarre leiomyoma (BL), smooth muscle tumours of uncer-
tain malignant potential (UMP) and leiomyosarcoma (LMS).
Benign smooth muscle tumours are common in the uterus, but
LMS is a rare tumour, accounting for only about 1.3% of all
uterine malignancies (Zaloudek et al, 1994). Uterine LMS usually
exhibits an extremely malignant clinical course. The risk of local
recurrence and metastasis is high in LMS and the reported 5-year
survival rate in cases of uterine LMS is only 12–25% (Zaloudek
et al, 1994). The marked difference in prevalence seen between
leiomyoma and leiomyosarcoma of the uterus suggests that
different mechanisms may underlie the development of these two
kinds of smooth muscle tumours.
Alterations in a number of oncogenes and tumour-suppressor
genes, resulting in an imbalance between cellular proliferation and
programmed cell death (apoptosis), are required for tumour
progression (Korsmeyer et al, 1992; Kerr et al, 1994). It has been
reported that both overexpression and mutation of tumour-
suppressor gene p53 are exhibited by uterine LMSs but not by
leiomyomas (de Vos et al, 1994; Jeffers et al, 1995; Zhai et al,
1998), suggesting that a loss of p53 function is implicated in the
pathogenesis of LMSs. The wild-type p53 inhibits cell cycling, in
cooperation with cyclin-dependent kinase (cdk) inhibitors such as
p21 and p27, and induces apoptosis (Yonish-Rouach et al, 1991;
Shaw et al, 1992; Hartwell et al, 1994). By contrast, mutant p53
can inhibit apoptosis and stimulate cell division and proliferation
(Lotem et al, 1993). Mutation or overexpression of p53 is found
increasingly as the stage of the disease advances, implying that
p53 alterations occur late in tumour development (Pollock et al,
1996). Moreover, it has been reported that p53 overexpression
correlates with a poor prognosis in a number of malignancies
(Borg et al, 1995; Lim et al, 1996; Uchiyama et al, 1997).
It is known that bcl-2, as well as p53, is involved in cell cycle
regulation and apoptosis (Williams et al, 1991). The bcl-2 proto-
oncogene encodes a 26 kDa protein mainly localized in mitochon-
drial membranes and this bcl-2 protein has been shown to prolong
cell survival by inhibiting the apoptotic processes induced by
many anticancer drugs, radiation and DNA-damaging agents,
processes that are mediated by p53 (Hockenbery et al, 1990;
Sentman et al, 1991; Korsmeyer et al, 1992; Miyashita et al, 1993;
Wang et al, 1993). bcl-2 expression has been demonstrated in a
variety of human cancers (Colombel et al, 1993; Joensuu et al,
1994) and it has been reported that bcl-2 expression is of prog-
nostic significance in a number of malignancies (Baretton et al,
1996; Nakanishi et al, 1997; Nakopoulou et al, 1998), as is the
expression of p53. In some cancers, bcl-2 expression correlates
with negative p53 staining (which implies the presence of wild-
type p53) (Silvestrini et al, 1994; Alderson et al, 1995; Fontanini
et al, 1995). Mutant p53 can substitute functionally for bcl-2 and
can down-regulate bcl-2 expression (Haldar et al, 1994),
suggesting that bcl-2 expression should be more common in
tumours containing wild-type p53 (Silvestrini et al, 1994;
Alderson et al, 1995). Thus, the relationship between bcl-2 and
p53 in malignant tumours is of interest, but very few studies have
involved simultaneous investigation of both bcl-2 and p53 expres-
sion in uterine LMSs. In this study, we investigated the expression
of bcl-2 and p53, as well as of p53 mutation, in uterine smooth
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muscle tumours and we assessed the prognostic significance of
these molecules in cases of LMS.
MATERIALS AND METHODS
Tissue collection
Sixty-seven patients (32–70 years of age) diagnosed as having
smooth muscle tumours of the uterus were selected from the
pathology file of Shinshu University Hospital. The tissues were
used after obtaining written consent from the patients or their next
of kin. Tissue blocks, proteins and DNA were prepared from the
removed uteri. The fresh tissues were fixed in 10% phosphate-
buffered formalin and embedded in paraffin. Serial sections were
prepared for haematoxylin and eosin staining, immunohisto-
chemistry and p53-mutation analysis. The pathological diagnosis
of uterine smooth muscle tumours was performed using the
accepted criteria (Hendrickson et al, 1995). Mitotic activity was
evaluated by counting the number of mitoses in ten consecutive
high-power fields and it was expressed as a mitotic index (MI). In
this study, the diameter of one high-power field (HPF) was
approximately 0.65 mm. Of the 67 cases of smooth muscle
tumours, 21 were diagnosed as LMS, eight were smooth muscle
tumours of UMP, eight were BL, 15 were CL and 15 were UL.
From these cases, fresh uterine tissues (from ten cases of normal
myometrium, ten cases of UL and three cases of LMS) were used
for Western blotting, and paraffin sections of 21 LMSs and 25
leiomyomas (five ULs, four CLs, eight UMPs and eight BLs)
were used for DNA sequencing. The clinical stage of LMS was
determined according to the FIGO classification of endometrial
carcinomas (Creasman et al, 1989). Clinical information,
including follow-up data, was obtained from the medical records.
Immunohistochemistry
Immunohistochemical analysis for bcl-2, p53 and Ki-67 was
performed on serial paraffin sections of the 67 smooth muscle
tumours. In cases of LMS, we employed at least two different
tissue blocks from each case. The p53 staining and Ki-67 labelling
index data for all the leiomyomas and 14 out of the 21 leiomyo-
sarcomas have already been reported by us (Zhai et al, 1998), and
those data were included in our assessment of the correlation
between p53 and bcl-2 expression in the present study. The
primary antibodies used were bcl-2 (Dako, Copenhagen,
Denmark), p53 (DO-1; Immunotech, Marseille, France) and Ki-67
(MIB-1; Immunotech). The avidin–biotin–peroxidase complex
method was performed using a Histofine SAB-PO (M) detector kit
(Nichirei, Tokyo, Japan). In brief, the sections were deparaffinized
in xylene, rehydrated through graded alcohols and treated in a
0.01 M citrate buffer (pH 6.0) for 15 min in a microwave oven.
They were then incubated with 0.03% hydrogen peroxide to block
endogenous peroxidase activity, and with normal rabbit serum to
reduce non-specific binding. The sections were incubated with a
specific primary antibody or non-immunized mouse serum at 4°C
overnight. Biotinylated rabbit anti-mouse IgG was used as a linker.
The sections were incubated with the streptavidin–biotin complex
and stained with diaminobenzidine. The sections were lightly
counterstained with haematoxylin.
Interpretation of immunohistochemical staining
The staining of p53 and bcl-2 was interpreted independently by
three observers (YZ, TT and SF). The results, based on the
percentage of stained cells among 1000 arbitrarily selected tumour
cells, were expressed as follows: ++, diffusely positive (more than
50% of the tumour cells were stained); +, partially positive
(5–49% of the cells were stained); and –, negative (less than 5% of
the cells were stained). The percentage of Ki-67-positive cells
among 1000 arbitrarily selected tumour cells was also counted and
the result was expressed in the form of a Ki-67 labelling index.
Western blot analysis
To confirm the antigenic specificity of the antibody used and also
to obtain quantitative information, the expression of bcl-2 protein
was examined by Western blotting. Fresh uterine tissues (normal
myometrium, ten cases; usual leiomyoma, ten cases; leiomyo-
sarcoma, three cases) were homogenized using a Polytron
(Kinematica, Switzerland), then lysed in 1 ml of cell-lysis buffer.
The buffer contained 50 mM Tris–HCl (pH 8.0), 0.25 M sodium
chloride, 0.5% NP-40, 1 mM phenylmethyl sulphoxide (Sigma),
1 mg ml–1 aprotinin (Boehringer Mannheim, Mannheim,
Germany), 1 mg ml–1 leupeptin (Boehringer Mannheim) and
20 mg ml–1 TPCK (Boehringer Mannheim). Lysates were
centrifuged at 13 000 g for 20 min at 4°C and the supernatants
were stored at –80°C. Extracts equivalent to 50 mg of total protein
were separated by sodium dodecyl sulphate polyacrylamide gel
electrophoresis (12% acrylamide gel), followed by the equilibra-
tion of the gel in transfer buffer (20% methanol, 25 mM Tris,
192 mM glycine, pH 8.0) for 30 min. The proteins were then
transferred to supported nitrocellulose membranes (Gibco BRL,
Gaithersburg, MD, USA) by applying 2400 V-min using a plate-
electrode apparatus (Idea Scientific, Minneapolis, MN, USA).
Filters were blocked for 1 h in TBST (0.2 M sodium chloride,
10 mM Tris, pH 7.4, 0.2% Tween-20) containing 5% non-fat dry
milk and 0.02% sodium azide. This was followed by incubations
with monoclonal antibodies for bcl-2 (1:500 dilution; Dako) and
b-actin (1:2000 dilution; AC-15, Biomakor, Rehovot, Israel, as the
internal standard) in TBST containing 5% non-fat milk overnight
at 4°C, then with anti-mouse IgG (1:1000; Amersham, Arlington
Heights, IL, USA) in TBST containing 2% non-fat milk. The
filters were washed several times with TBST between steps.
Bound antibody was detected by means of an enhanced chemi-
luminescence (ECL) system (Amersham, Aylesbury, UK) and
exposed to X-ray films.
Polymerase chain reaction-DNA sequencing of p53
To help us determine whether overexpression of p53 is caused by a
mutation of the p53 gene, we examined the sequences of the DNA
from all the 21 LMSs and 25 of the leiomyomas (including those
with positive p53 staining) using the DyeDeoxy method. The
sequence analysis of the p53 gene in 14 out of the 21 leiomyosar-
comas and in the same 25 leiomyomas has already been reported
by us (Zhai et al, 1998). In the present study, we studied p53 muta-
tion in seven more cases of leiomyosarcoma, and we are reporting
the results of all the cases together in this paper. DNAs were
extracted from paraffin-embedded consecutive tissue sections
using the microwave-based DNA extraction method for poly-
merase chain reaction (PCR) amplification (Banerjee et al, 1995).
Exons 5–8 were amplified by PCR according to the published
sequencing of oligonucleotide primers, as described previously
(Oda et al, 1992). After heating at 94°C for 2 min, all samples of
genomic DNA underwent thermocycling for 35 cycles (94°C for1 min, 58°C or 60°C for 1 min, 72°C for 2 min) using a Gene Taq
Kit (Nippon Gene, Toyama, Japan). To confirm the success of the
PCR reaction for each DNA sample, 5 ml of PCR product were
electrophoresed on a 2% agarose gel, then each product was puri-
fied using a DNA recollectional filter tube (TaKaRa suprec-TM02;
Takara, Japan). The nucleotide sequences were determined by the
dideoxynucleotide-chain-termination method using a Tag Dye-
deoxy Terminator Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA, USA).
Statistical analysis
The Kruskal–Wallis rank test and Scheffé’s F test were used to
examine the significance of differences in the Ki-67 labelling
index among the smooth muscle tumours. Spearman’s rank corre-
lation was used to determine whether there was a significant posi-
tive or negative correlation between any two of the results. Cox’s
proportional hazard model was used to identify the significant
predictors of survival (SPSS v7.5; SPSS Inc., Chicago, IL, USA).
The prognostic factors used in the survival analysis were the
following: the age of the patient (< 50 vs ³ 50), clinical stage
(1 vs 2,3 and 4), mitotic index (< 50 vs ³ 50), bcl-2 expression
(< 5% vs ³ 5%), p53 overexpression (< 5% vs ³ 5%), p53 muta-
tion (positive vs negative) and the Ki-67 labelling index (< 25% vs
³ 25%). Since all the six cases whose disease was at stage 3 or 4
had died of their disease, the comparison was performed between
stage 1 and stages 2–4. The cut-off values for the mitotic index and
the Ki-67 labelling index were chosen so that the P-value became
minimal in the univariate analysis. The univariate analysis was
first performed on each of the factors. Overall survival was then
analysed by means of the step-wise regression model (forward)
using those variables with a P-value of < 0.4 in the univariate
analysis. A P-value less than 0.05 was considered significant.
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Table 1 Results of immunohistochemistry for bcl-2 and p53 in smooth
muscle tumours of the uterus
History bcl-2 p53
MY (n = 15) –/+ –
UL (n = 15) +/++ –
CL (n = 15) +/++ –
BL (n = 8) +/++ –/+
UMP (n = 8) +/++ –/+
LMS (n = 21) –/++ –/++
MY, myometrium; UL, usual leiomyoma; CL, cellular leiomyoma; BL, bizarre
leiomyoma; UMP, tumours of uncertain malignant potential; LMS,
leiomyosarcoma.
AB
CD
Figure 1 Immunohistochemical staining for bcl-2. (A) Normal myometrium showing focal positive staining for bcl-2, (B) leiomyoma showing diffuse positive
staining for bcl-2, (C) a case of leiomyosarcoma showing positive staining for bcl-2 and (D) another case of leiomyosarcoma showing negative staining for bcl-2
(original magnification ´ 400)bcl-2 and p53 expression in uterine smooth muscle tumours 1661
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RESULTS
Immunohistochemistry in uterine smooth muscle
tumours
Specific staining was identified as a brown colour in the nuclei for
p53 and Ki-67 and in the cytoplasm for bcl-2. All the control slides
yielded negative staining. The results of the immunohistochem-
istry are summarized in Table 1 for the various uterine smooth
muscle tumours. Normal myometrial tissue adjacent to the benign
smooth muscle tumours was focally positive for bcl-2 (Figure 1A).
All the cases of UL, CL, BL and UMP were diffusely positive for
bcl-2 (Figure 1B), except for three cases in which bcl-2 expression
was equivocal, and the staining intensity was generally stronger in
the leiomyomas than in the myometria. Of the 21 cases of LMS,
nine (43%) were partially positive and three (14%) were diffusely
positive for bcl-2 (Figure 1C), while nine (43%) were negative
(Figure 1D). Lymphocytes scattered in the smooth muscle tumours
were often positive for bcl-2 as well. UL, CL, most UMP, most BL
and the adjacent myometrium were negative for p53 (Figure 2A)
but one (out of nine) UMP and two (out of nine) BLs were
partially positive for p53. Of the 21 LMSs, 16 (76%) were
partially or diffusely positive for p53 (Figure 2B) and five were
negative (Table 2). The Ki-67 labelling index was significantly
higher in LMS (32.0 ± 12.0; mean ± s.d.) than in UL (0.5 ± 0.3),
CL (0.6 ± 0.5), BL (0.5 ± 0.6) or UMP (1.5 ± 1.0) (P < 0.001).
Western blotting of bcl-2
Tissue samples from myometrium or leiomyoma showed a
specific band for bcl-2 with a molecular weight of 26 kDa
(Figure 3, lanes 1–6). Among the samples from leiomyosarcomas,
two (Figure 3, lanes 7 and 8; cases 17 and 18 in Table 2) showed
weak bands and one (Figure 3, lanes 9; case 20 in Table 2)
showed a strong specific band for bcl-2 (Figure 3). These results
were compatible with those obtained by immunostaining.
Detection of p53 mutation
No mutation of the p53 gene was detected in any of the 25 leiomy-
omas (including the one UMP and two BLs that showed positive
staining for p53). In LMS, a mis-sense mutation of the p53 gene
was detected in nine specimens. Of these nine, one showed a
mutation in exon 5, two a mutation in exon 6 and in exon 7, and
four a mutation in exon 8. All of these nine cases were diffusely
positive for p53 by immunostaining. However, no mutation was
detected in the remaining 13 LMSs, irrespective of their p53
immunoreactivity (Table 2).
Relationships among clinical stage, mitotic index,
immunohistochemical results and p53 mutation in
leiomyosarcoma
Table 3 summarizes the correlations between pairs of the
following factors in cases of LMS: clinical stage, mitotic index,
bcl-2 expression, p53 expression, p53 mutation and the Ki-67
labelling index. Significant positive correlations were observed
between p53 expression and p53 mutation (correlation coefficient
0.65, P < 0.005), between stage and p53 mutation (correlation
coefficient 0.59, P < 0.005) and between mitotic activity and the
Ki-67 labelling index (correlation coefficient 0.47, P < 0.05). On
the other hand, significant negative correlations were observed
between bcl-2 expression and p53 mutation (correlation coeffi-
cient –0.62, P < 0.005) and between bcl-2 expression and p53
expression (correlation coefficient –0.45, P < 0.05).
Survival analysis
Among the 21 patients with LMS, 12 had died of their disease
and nine were alive with no evidence of disease. The mean
Table 2 Clinical profile, Ki-67, bcl-2 and p53 expression, p53 mutation and survival in cases with uterine leiomyosarcoma
Case Age Stage MI Ki-67 bcl-2 p53
p53 mutation
Survival
(%) stain Codon Base change (Amino acid) (months)
1a 37 4 97 25 – ++ 249 AGG to TGG (Arg to Trp) D (1)
2 69 4 87 52 – ++ 276 GCC to GAC (Ala to Asp) D (8)
3 70 4 133 43 – ++ 205 TAT to TGT (Tyr to Cys) D (5)
4 39 3 85 45 – ++ 273 CGT to CAT (Arg to His) D (8)
5a 65 1 30 23 – ++ 303 AGC to ATC (Ser to Ile) D (20)
6 56 1 53 41 – ++ 173 GTG to ATG (Val to Met) A (6)
7 51 1 43 25 – ++ 215 AGT to AGG (Ser to Arg) D (2)
8a 49 1 46 48 – ++ ND D (24)
9a 52 1 107 37 – + ND D (13)
10a 45 2 32 33 + ++ 285 GAG to GAC (Glu to Asp) D (24)
11a 58 3 24 32 + + 248 CGG to CAG (Arg to Gln) D (23)
12a 43 3 57 22 + – ND D (10)
13a 55 1 75 46 + – ND D (18)
14a 67 1 23 21 + – ND A (41)
15 43 2 87 51 + – ND A (14)
16a 51 1 93 38 + – ND A (101)
17a 67 1 64 29 + + ND A (22)
18a 67 1 37 19 + + ND A (23)
19a 51 1 22 13 ++ + ND A (41)
20 63 2 43 31 ++ + ND A (17)
21a 48 1 14 24 ++ ++ ND A (66)
MI, mitotic index; Ki-67, Ki-67 labelling index; D, died of disease; A, alive with no evidence of disease; ND, not detected. aKi-67 labelling index, p53 staining and
p53 gene mutations in these cases have been reported by our previous study (Zhai et al, 1998).post-operative observation period was 34.7 ± 30.3 months. A
univariate analysis using Cox’s proportional hazard model
revealed that the prognosis was significantly poorer in patients (i)
with negative bcl-2 expression (P < 0.005), (ii) with a p53 muta-
tion (P < 0.01) and (iii) nine cases at stages 2, 3 or 4 as compared
to 12 cases at stage 1 (P < 0.05) (Table 4). The age of the patients
(P = 0.64) was not included in the step-wise regression. The
step-wise regression analysis (forward) was performed using six
variables (clinical stage, mitotic index, bcl-2 expression, p53
staining, p53 mutation status and the Ki-67 labelling index).
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AB
Figure 2 Immunohistochemical staining for p53. (A) Usual leiomyoma showing negative staining for p53, (B) leiomyosarcoma showing diffuse positive staining
for p53 (original magnification ´ 400)
Table 3 Correlations between the clinicopathological parameters examined
in uterine leiomyosarcoma
Mitotic bcl-2 p53 p53 Ki-67
index expression expression mutation index
Clinical stage 0.33 –0.28 0.3 0.59b 0.31
Mitotic index –0.33 0.1 –0.03 0.47a
bcl-2 expression –0.45a –0.62b –0.42
p53 expression 0.65b 0.093
p53 mutation 0.17
Data are presented as correlation coefficients; a P < 0.05; b P < 0.005.
1 2 3 4 5 6 7 8 9
26
42
kDa
bcl-2
b-actin
Figure 3 Results of Western blotting for bcl-2 and b-actin. Lanes 1–3:
myometrium, lanes 4–6: leiomyoma, lanes 7–9: leiomyosarcomas.
Myometrium and leiomyoma are showing specific bands for bcl-2 (molecular
weight 26 kDa). The cases in lanes 7 and 8 (weak bands) correspond to
cases 17 and 18 in Table 2, and the case in lane 9 (distinct band)
corresponds to case 20 in Table 2
Table 4 Univariate and stepwise regression analyses of the prognostic value of clinical and histopathological variables in 21 patients with uterine
leiomyosarcoma
Disease-free survival
Prognostic Univariate RR Stepwise RR
factor (P) (CI) (P) (CI)
Age <50 0.64 1.3 (0.4–4.2) not included
Stages 2, 3 and 4 0.041a 3.4 (1.1–11.3) 0.0083b 9.3 (1.8–48.9)
Mitotic index >50 0.082 3.0 (0.9–10.0) 0.086
Negative bcl-2 0.0028c 6.6 (1.9–22.5) 0.0012c 15.4 (3.0–80.6)
Positive p53 staining 0.39 1.9 (0.4–8.9) >0.4
Positive p53 mutation 0.0062b 5.5 (1.6–18.7) >0.4
Ki-67 labelling index > 25 0.079 3.9 (0.9–18.0) >0.2
RR, relative risk; CI, 95% confidence intervals; a P < 0.05; b P < 0.01; c P < 0.005.bcl-2 and p53 expression in uterine smooth muscle tumours 1663
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A longer disease-free survival was significantly correlated with
positive bcl-2 expression (P = 0.0012) and stage 1 disease
(P = 0.0083, as compared to stages 2–4) (Table 4).
DISCUSSION
This study has revealed the presence of a stronger bcl-2 expression
in benign uterine smooth muscle cell tumours (UL, CL, BL and
UMP) than in the normal myometrium or in leiomyosarcomas.
The Western blotting experiments supported this evidence of an
over-production of bcl-2 protein in these benign tumours. The
benign leiomyomas showed negative or weak positive staining for
p53, no p53 mutation and a low Ki-67 labelling index. The bcl-2
overexpression in benign uterine smooth muscle tumours suggests
that it might play an important role in preventing apoptosis among
benign neoplastic smooth muscle cells. Although bcl-2 itself does
not stimulate cell growth, an inhibition of apoptosis by bcl-2 may
provide a survival advantage to the cells of benign uterine smooth
muscle tumours. However, since cellular proliferation and apop-
tosis form a complex mechanism, another pathway, not involving
bcl-2 and p53, could also be implicated in the regulation of the cell
cycle and cell growth in benign leiomyomas of the uterus.
In the leiomyosarcomas, we noted a strong positive correlation
between p53 expression and p53 mutation. While wild-type p53
was generally correlated with weak or negative p53 staining.
However, in a few cases, there was an apparent discrepancy
between p53-mutation status and p53 staining. In fact, half of the
tumours that were positive for p53 did not show a mutation in
exons 5–8 of the p53 gene examined, but it is possible that abnor-
malities of the p53 gene were present in other exons. To judge
from these results, although the overall correlation between p53
mutation and p53 expression is very good, p53 staining may not be
completely consistent with p53-mutation status.
In this study, a strong negative correlation was found between
bcl-2 expression and p53 mutation, and a less significant one was
found between bcl-2 expression and p53 expression. Previously,
an inverse correlation between bcl-2 and p53 expression has been
reported in a number of human malignancies (Pezzella et al, 1993;
Silvestrini et al, 1994; Alderson et al, 1995; Fontanini et al, 1995;
Kaklamanis et al, 1998). Most of these studies were performed
using immunohistochemical methods alone and only one investi-
gated p53 mutation simultaneously (Alderson et al, 1995, Lepelley
et al, 1995). The results of the present study suggest that p53 muta-
tion, rather than p53-positive staining or immunoreactivity, is
inversely correlated with bcl-2 expression. Interestingly, a fairly
recent study indicated that mutant p53 can down-regulate bcl-2
expression in breast cancer cells (Haldar et al, 1994). These
results, taken together, suggest that the reduced expression of bcl-
2 seen in some leiomyosarcomas might well have been induced by
mutant p53. However, wild-type p53 induces a decrease in bcl-2
expression in vitro (Miyashita et al, 1994), while in vivo studies on
human malignant tumours (including the present study) have
shown that weak p53 expression, which indicates that p53 is not
mutated but of the wild type, is correlated with an increased bcl-2
expression (Pezzella et al, 1993; Silvestrini et al, 1994; Alderson
et al, 1995). Since diffuse cell loss by apoptosis eventually leads to
an arrest of tumour growth, a regulation of apoptosis would be an
appropriate target for genetic changes associated with malignant
tissue transformation. Our results suggest that an inhibition of the
induction of apoptosis – either by bcl-2 overexpression (in most of
the benign leiomyomas and almost a half of the leiomyosarcomas)
or by p53 inactivation due to its mutation (in the remaining half of
the leiomyosarcomas) – might be a common phenomenon in
human uterine smooth muscle tumours.
It has been reported that clinical stage (Wolfson et al, 1994;
Nola et al, 1996), tumour size (Evans et al, 1988), mitotic activity
(Major et al, 1993), DNA index (Wolfson et al, 1994) and p53
overexpression (Niemann et al, 1995) correlate with prognosis in
uterine leiomyosarcomas. In the present study, a univariate
survival analysis showed that survival was significantly correlated
with bcl-2 expression, p53 mutation and clinical stage. A subse-
quent step-wise regression analysis revealed that bcl-2 expression
and clinical stage 1 disease (as compared to stages 2–4) were the
best independent predictors of a favourable prognosis. In fact, the
prognostic significance of bcl-2 expression has already been
reported in a number of malignancies. Most reported a favourable
prognosis in patients with tumours positive for bcl-2 (Pezzella et
al, 1994; Silvestrini et al, 1994; Fontanini et al, 1995; Kaklamanis
et al, 1998), although bcl-2 expression correlated with a poor
prognosis in another report (Brambilla et al, 1996). Thus, the prog-
nostic significance of bcl-2 may vary among different types of
malignant tumours. Although the biological significance of bcl-2
expression in malignant tumours is not entirely clear, bcl-2 expres-
sion does appear to play an important role in the growth of human
carcinomas. In particular, the diffuse bcl-2 expression in benign
uterine smooth muscle tumours and the good clinical outcome of
LMSs with a bcl-2 expression together suggest that bcl-2 might
possibly be involved in the inhibition of tumour progression or
spread.
In conclusion, the present study has shown that bcl-2 is
frequently expressed in human uterine smooth muscle tumours. A
significant positive correlation between clinical stage and p53
mutation status and a significant negative correlation between bcl-
2 expression and p53-mutation status was observed among uterine
leiomyosarcomas. A multivariate survival analysis revealed that
bcl-2 expression and stage 1 disease (as compared to stages 2–4)
were significantly correlated with a favourable prognosis in
patients with uterine leiomyosarcoma.
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